Mobile

An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005496-10

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare R-CHOP plus enzastaurin versus R-CHOP in terms of the elapsed progression-free survival (PFS) time measured in patients with intermediate and/or high-risk DLBCL receiving first-line treatment.

Critère d'inclusion

  • First-Line Diffuse Large B-Cell Lymphoma

Liens